Oral lichenoid reactions associated with anti‐<scp>PD</scp>‐1/<scp>PD</scp>‐L1 therapies: clinicopathological findings
V. Sibaud(Institut Claudius Regaud), Mario E. Lacouture(Garden City Community College), Laurence Lamant(Centre National de la Recherche Scientifique), Cherry L. Estilo(Memorial Sloan Kettering Cancer Center), Émmanuelle Vigarios(Institut Claudius Regaud), Robert J. Motzer(Memorial Sloan Kettering Cancer Center), P. Combemale(Centre Léon Bérard), Viswanath Reddy Belum(Memorial Sloan Kettering Cancer Center), Béatrice Barres(Institut Claudius Regaud), C Gomez-Roca(Institut Claudius Regaud), Loı̈c Mourey
Cited by 75
Related Papers
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
|New England Journal of Medicine|2018|4.6k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|645
Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2019|560